Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2014; 20(42): 15650-15656
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15650
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15650
Area of study | Study design | Route of administration | Study phase | Treatment effect | Sample size/ Estimated enrollment1 | Ref.1 |
Completed trials | ||||||
Coronary artery bypass | Randomized, placebo | Intravenous | 2 | Increased endogenous alkaline phosphatase release | 32 | Kats et al[47] (2012) |
Severe sepsis and septic shock on acute kidney injury | Double-blind, randomized and placebo | Intravenous | 2 | Improved renal function | 36 | Heemskerk et al[49] (2009) |
Moderate to severe ulcerative colitis | Uncontrolled | Oral | 2 | Short term improvement of moderate/severe ulcerative colitis | 20 | Lukas et al[50] (2010) |
Sepsis in patients with acute kidney injury (AKI) | Double-blind, randomized and placebo | Intravenous | 2 | Renal protection from sepsis in patients with AKI | 36 | Pickers et al[48] (2012) |
Ongoing trials | ||||||
Acute rheumatoid arthritis | Non-randomized | Subcutaneous | 1 and 2 | Ongoing study | 10 | NCT014164932 |
Safety and efficacy during heart surgery | Randomized double-blind, placebo-controlled | Intravenous | 3 | Ongoing study | 228 | NCT011446112 |
- Citation: Estaki M, DeCoffe D, Gibson DL. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. World J Gastroenterol 2014; 20(42): 15650-15656
- URL: https://www.wjgnet.com/1007-9327/full/v20/i42/15650.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i42.15650